Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction
Portfolio Pulse from Benzinga Newsdesk
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) has begun initial dosing in a Phase 1 trial of EDG-7500, a first-in-class oral, selective, cardiac sarcomere modulator for Hypertrophic Cardiomyopathy (HCM) and other diseases of cardiac diastolic dysfunction. The trial will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of EDG-7500 in healthy adults. A Phase 1b study of EDG-7500 in individuals with obstructive HCM is planned for the first half of 2024.
September 14, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Edgewise Therapeutics has initiated a Phase 1 trial for its lead clinical candidate, EDG-7500. This could potentially lead to a new treatment for HCM and other cardiac diseases, which would be a significant development for the company.
The initiation of the Phase 1 trial for EDG-7500 is a significant step for Edgewise Therapeutics. If successful, it could lead to a new treatment for HCM and other cardiac diseases, which would be a major development for the company and could potentially boost its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100